Rice Hall James & Associates LLC Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Rice Hall James & Associates LLC reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,730 shares of the medical equipment provider’s stock after selling 3,410 shares during the period. Rice Hall James & Associates LLC owned approximately 0.07% of Lantheus worth $4,366,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Summit Securities Group LLC purchased a new position in shares of Lantheus during the 4th quarter worth about $37,000. Hughes Financial Services LLC purchased a new position in shares of Lantheus during the 1st quarter worth about $81,000. UMB Bank n.a. boosted its stake in shares of Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 381 shares during the period. Blue Trust Inc. boosted its stake in shares of Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 633 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 298 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. B. Riley dropped their price target on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research note on Monday, June 23rd. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $131.20.

Lantheus Price Performance

Lantheus stock opened at $81.31 on Monday. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of 23.10 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The firm has a 50-day moving average of $80.26 and a two-hundred day moving average of $89.91.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. Lantheus’s quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the firm earned $1.69 earnings per share. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.